250 related articles for article (PubMed ID: 28114597)
1. Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome.
Formiga MNDC; de Andrade KC; Kowalski LP; Achatz MI
JAMA Oncol; 2017 Oct; 3(10):1400-1402. PubMed ID: 28114597
[TBL] [Abstract][Full Text] [Related]
2. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
3. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
4. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
5. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.
Giacomazzi J; Selistre S; Duarte J; Ribeiro JP; Vieira PJ; de Souza Macedo G; Rossi C; Czepielewski M; Netto CB; Hainaut P; Ashton-Prolla P
BMC Cancer; 2013 Apr; 13():187. PubMed ID: 23570263
[TBL] [Abstract][Full Text] [Related]
6. Identification of the
Sandoval RL; Masotti C; de Macedo MP; Ribeiro MFSA; Leite ACR; Meireles SI; Bovolin RM; Santini FC; Munhoz RR; Jardim DLF; Katz A; Camargo AA; Fernandes GDS; Achatz MI
JCO Glob Oncol; 2021 Jul; 7():1141-1150. PubMed ID: 34270331
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by
Sandoval RL; Polidorio N; Leite ACR; Cartaxo M; Pisani JP; Quirino CV; Cezana L; Pereira NG; Pereira AAL; Rossi BM; Achatz MI
Front Oncol; 2022; 12():836937. PubMed ID: 35371985
[TBL] [Abstract][Full Text] [Related]
9. The Brazilian founder mutation TP53 p.R337H is uncommon in Portuguese women diagnosed with breast cancer.
Giacomazzi J; Correia RL; Palmero EI; Gaspar JF; Almeida M; Portela C; Camey SA; Monteiro A; Pinheiro M; Peixoto A; Teixeira MR; Reis RM; Ashton-Prolla P
Breast J; 2014; 20(5):534-6. PubMed ID: 25052705
[TBL] [Abstract][Full Text] [Related]
10. Early-onset breast cancer patients in the South and Southeast of Brazil should be tested for the TP53 p.R337H mutation.
Andrade KC; Santiago KM; Fortes FP; Mambelli LI; Nóbrega AF; Achatz MI
Genet Mol Biol; 2016 May; 39(2):199-202. PubMed ID: 27223487
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil.
Giacomazzi J; Graudenz MS; Osorio CA; Koehler-Santos P; Palmero EI; Zagonel-Oliveira M; Michelli RA; Scapulatempo Neto C; Fernandes GC; Achatz MI; Martel-Planche G; Soares FA; Caleffi M; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
PLoS One; 2014; 9(6):e99893. PubMed ID: 24936644
[TBL] [Abstract][Full Text] [Related]
12. The Brazilian TP53 mutation (R337H) and sarcomas.
Volc SM; Ramos CRN; Galvão HCR; Felicio PS; Coelho AS; Berardineli GN; Campacci N; Sabato CDS; Abrahao-Machado LF; Santana IVV; Campanella N; Lengert AVH; Vidal DO; Reis RM; Dantas CF; Coelho RC; Boldrini E; Serrano SV; Palmero EI
PLoS One; 2020; 15(1):e0227260. PubMed ID: 31978118
[TBL] [Abstract][Full Text] [Related]
13. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
Petry V; Bonadio RC; Cagnacci AQC; Senna LAL; Campos RDNG; Cotti GC; Hoff PM; Fragoso MCBV; Estevez-Diz MDP
Fam Cancer; 2020 Jan; 19(1):47-53. PubMed ID: 31748977
[TBL] [Abstract][Full Text] [Related]
15. Functional pri-miR-34b/c rs4938723 and KRAS 3'UTR rs61764370 SNPs: Novel phenotype modifiers in Li-Fraumeni Syndrome?
Vieira IA; Pezzi EH; Bandeira IC; Reis LB; de Araújo Rocha YM; Fernandes BV; Siebert M; Miyamoto KN; Siqueira MB; Achatz MI; Galvão HCR; Garcia FAO; Campacci N; Carraro DM; Formiga MN; Vianna FSL; Palmero EI; Macedo GS; Ashton-Prolla P
Gene; 2024 Mar; 898():148069. PubMed ID: 38070788
[TBL] [Abstract][Full Text] [Related]
16. MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers.
Bandeira IC; Vieira IA; Andreis TF; Brussa Reis L; Macedo GS; Vianna FSL; Santos-Silva P; Palmero EI; Galvão HCR; Ramos CRN; Santiago KM; Achatz MI; da Costa AABA; Ashton-Prolla P
Cancer Genet; 2020 Jan; 240():54-58. PubMed ID: 31778928
[TBL] [Abstract][Full Text] [Related]
17. The Clinical and Molecular Profile of Lung Cancer Patients Harboring the
Lopes CDH; Antonacio FF; Moraes PMG; Asprino PF; Galante PAF; Jardim DL; de Macedo MP; Sandoval RL; Katz A; de Castro G; Achatz MI
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894716
[TBL] [Abstract][Full Text] [Related]
18. The Common Germline
Jeffers JR; Pinto EM; Rehg JE; Clay MR; Wang J; Neale G; Heath RJ; Lozano G; Lalli E; Figueiredo BC; Pappo AS; Rodriguez-Galindo C; Chen W; Pounds S; Ribeiro RC; Zambetti GP
Cancer Res; 2021 May; 81(9):2442-2456. PubMed ID: 33637564
[TBL] [Abstract][Full Text] [Related]
19. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
[TBL] [Abstract][Full Text] [Related]
20. TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families.
Cury NM; Ferraz VE; Silva WA
Hered Cancer Clin Pract; 2014 Mar; 12(1):8. PubMed ID: 24625245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
